Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential CD20/CD22/CD10-CART after CD19-CART in B-ALL
NCT03407859Phase 1Recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Jan 2016
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD20 + CD22 + CD10 chimeric antigen receptor T-cell therapy in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Adverse events related to treatment at 2 years. Started Jan 2016; status: recruiting.
02
Drugs
CD20 + CD22 + CD10 chimeric antigen receptor T-cell therapy
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03407859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03407859.